Ambrx Biopharma Inc. (NYSE:AMAM – Get Rating) major shareholder Cormorant Asset Management, Lp purchased 250,000 shares of the company’s stock in a transaction dated Tuesday, March 14th. The stock was purchased at an average price of $9.95 per share, with a total value of $2,487,500.00. Following the completion of the purchase, the insider now directly owns 52,750,000 shares in the company, valued at approximately $524,862,500. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Cormorant Asset Management, Lp also recently made the following trade(s):
- On Thursday, March 16th, Cormorant Asset Management, Lp purchased 500,000 shares of Ambrx Biopharma stock. The stock was purchased at an average price of $10.15 per share, with a total value of $5,075,000.00.
Ambrx Biopharma Stock Down 11.8 %
Shares of NYSE:AMAM opened at $8.93 on Friday. Ambrx Biopharma Inc. has a 12-month low of $0.38 and a 12-month high of $13.07. The business has a fifty day simple moving average of $4.32 and a 200 day simple moving average of $2.30.
Analyst Upgrades and Downgrades
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its position in Ambrx Biopharma by 91.5% during the 1st quarter. Renaissance Technologies LLC now owns 22,600 shares of the company’s stock worth $93,000 after purchasing an additional 10,800 shares during the last quarter. B. Riley Wealth Advisors Inc. bought a new position in Ambrx Biopharma during the 4th quarter worth $45,000. FMR LLC raised its position in Ambrx Biopharma by 0.8% during the 2nd quarter. FMR LLC now owns 3,857,679 shares of the company’s stock worth $10,223,000 after purchasing an additional 32,320 shares during the last quarter. Royal Bank of Canada bought a new position in Ambrx Biopharma during the 3rd quarter worth $46,000. Finally, Alpine Global Management LLC bought a new position in Ambrx Biopharma during the 4th quarter worth $106,000. 43.14% of the stock is owned by institutional investors.
Ambrx Biopharma Company Profile
Ambrx Biopharma Inc, a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.
- Get a free copy of the StockNews.com research report on Ambrx Biopharma (AMAM)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.